<DOC>
	<DOCNO>NCT02600208</DOCNO>
	<brief_summary>This single arm pilot study patient hematologic malignancy alternative donor source receive unrelated partially matched related/Haploidentical mobilize peripheral stem cell ( PSCs ) use CliniMACS system Alpha Beta T cell depletion plus CD19+ B cell depletion determine efficacy determine engraftment GVHD , one year leukemia free survival .</brief_summary>
	<brief_title>Peripheral Blood Stem Cell Transplantation Hematologic Malignancies With Alpha Beta TCell B Cell Depletion Using CliniMACS Device</brief_title>
	<detailed_description>The purpose research study evaluate new method T cell depletion use Miltenyi CliniMACS™ device patient undergoing peripheral stem cell transplant utilize either unrelated donor partially matched/haploidentical relate donor . This new method call α/β ( alpha/beta ) T cell depletion CD19+ B cell depletion . This pilot study evaluate new method T cell B cell depletion effective way remove T cell thus reduce risk severe acute chronic GVHD result durable engraftment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patient : 1 . Age . Patient age &lt; 23 year . Both gender race eligible . 2 . Disease eligibility Leukemias/lymphomas : Acute myeloid leukemia , primary secondary Disease status : remission &lt; 10 % bone marrow blast Myelodysplasia Acute lymphoblastic leukemia Disease status : hematologic remission Chronic myelogenous leukemia : Disease status : chronic phase , accelerate phase blast crisis second chronic phase . Mixed lineage biphenotypic acute leukemia Lymphoblastic lymphoma Disease status : remission Burkitt 's lymphoma/leukemia : Disease status : remission Patient 1 . Patients meet disease , organ infectious criterion . 2 . No suitable donor</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>